medical cannabis is the focus for Tilray Medical at Cannabis Europa London 2026, where the company will join policymakers, clinicians, researchers and industry leaders to examine evidence, trials and regulatory approaches. Tilray Medical will appear on a May 26 panel at The Barbican in London titled “Evidence First: Designing Public Policy Through Data and Trials.” The session is scheduled for 12:00 p.m.
José Tempero, Director of International Medical Affairs at Tilray Medical, will take part in the panel. Speakers will review results from European pilot programmes, clinical research findings and real-world evidence and discuss how those data points are being used to shape national and regional medical cannabis frameworks. The panel agenda lists clinical trials, public health datasets, patient outcomes and options for scalable regulation as core topics.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) describes Tilray Medical as its medical division focused on research, cultivation, manufacturing and distribution. The company reports operations in more than 20 regulated international markets and says it has supported hundreds of thousands of patients worldwide with cannabinoid-based products, including CBD and THC formulations across multiple delivery formats. Tilray emphasizes pharmaceutical-quality cultivation and manufacturing and regulatory engagement with healthcare authorities.
Tempero said science, research and clinical evidence remain essential as European medical cannabis programmes change. He noted that combining clinical trial results with patient-reported outcomes from real-world settings helps regulators quantify product safety and treatment effects across patient groups. The panel will present examples of pilot programmes and study designs that regulators and clinicians can review when updating formularies, prescribing criteria and monitoring protocols.
Stephen Murphy, founder of Cannabis Europa and Prohibition Partners, underscored the event’s goal of sustained dialogue among regulators, clinicians, investors and industry. He said Tilray’s participation reflects growing international market access and that policy change depends on ongoing collaboration and scientific exchange. Murphy framed the conference as a platform for comparing national approaches to reimbursement, prescription pathways and post-market surveillance.
Tilray Medical will also promote its U.K. operations through Lyphe Clinic, its U.K.-based medical cannabis clinic and digital platform. Lyphe Clinic provides patient consultations, prescriptions and education and connects patients to Tilray Medical supply channels. For registered Cannabis Europa attendees, Tilray Medical and Lyphe Clinic will co-host the event’s official afterparty, opening additional networking opportunities with clinicians and policymakers.
Concrete topics slated for discussion at the panel include: – How pilot programmes in specific European countries have measured pain reduction, seizure frequency or quality-of-life outcomes and how those measurements influenced prescribing guidelines. – Trial designs that compare cannabinoid formulations to standard-of-care treatments or placebo controls, including sample sizes, endpoints and follow-up periods used to detect clinical effects. – Use of electronic health records and registries to gather post-prescription safety data and measure longer-term outcomes across age groups and comorbidities. – Regulatory models that allow limited access under medical supervision while collecting data to inform broader policy changes.
Tilray Medical frames its role as supporting clinicians and expanding patient access through education, product stewardship and compliant supply infrastructure. The company lists continued investment in clinical education and regulatory engagement among its priorities to maintain consistent product quality and supply chains across markets.
For clinicians and policymakers, the panel aims to present concrete study results and regulatory case studies rather than abstract recommendations. Attendees can expect references to specific trials and pilot outcomes, discussion of measurement methods for patient-reported outcomes, and comparisons of national regulatory pathways that have led to measurable changes in prescribing rates or access metrics.
Cannabis Europa London 2026 gathers stakeholders across Europe to compare data-driven policy approaches and to discuss next steps for clinical research and regulatory oversight. Tilray Medical’s participation, including its panel appearance and Lyphe Clinic involvement, signals the company’s intent to engage directly with regulators and medical professionals on measurable evidence and program designs that can be evaluated against public health objectives.
Panel details: “Evidence First: Designing Public Policy Through Data and Trials,” May 26, 12:00 p.m., The Barbican, London. Registered attendees can attend the afterparty co-hosted by Tilray Medical and Lyphe Clinic.
